Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC to Present at the 5th Annual Cell & Gene Therapy Investor Day on April 27, 2017
GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC to Present at the 29th Annual ROTH Conference on March 14, 2017
GAINESVILLE, Fla., and CAMBRIDGE, Mass., March 03, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC Selected as Top Company in the University of Florida's 2017 Gator100
Award Recognizes Fastest Growing Global Businesses Owned or Led by UF Graduates
View HTML
Toggle Summary AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2016
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
View HTML
Toggle Summary AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 8, 2017
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it
View HTML
Toggle Summary AGTC and Bionic Sight Announce Strategic Collaboration to Develop an Optogenetic Therapy and Device for Visual Deficits and Blindness
Innovative approach will combine AGTC's gene therapy expertise with Bionic Sight's neuro-prosthetic device to potentially restore retinal function
View HTML
Toggle Summary AGTC to Present at Phacilitate Cell & Gene Therapy World 2017
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Jan. 12, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced its
View HTML
Toggle Summary AGTC to Present at Upcoming Conferences
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced its
View HTML
Toggle Summary AGTC Appoints Michael Goldstein, M.D. as Chief Medical Officer
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the
View HTML
Toggle Summary AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2016
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
View HTML
Visionary science for life changing cures.